Company Overview of IDEA AG
IDEA AG develops and commercializes non-invasive targeted therapeutics applied through the skin for delivery of drugs. The company uses Transfersome cariers for transporting the established molecular weight drugs selectively into the skin. It focuses on dermatological and pain therapeutics. The company’s Diractin is a ketoprofen in the Transfersome gel for the treatment of peripheral pain. IDEA AG was founded in 1993 and is based in Munich, Germany.
Founded in 1993
49 89 3246330
49 89 32463394
Key Executives for IDEA AG
Similar Private Companies By Industry
|4 Animals AlsterScience GmbH||Europe|
|Acousia Therapeutics GmbH||Europe|
|Across Barriers GmbH||Europe|
|Actinodrug Pharmaceuticals GmbH||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|NYC2012, Inc.||United States|
|John F. Kennedy Center For The Performing Arts||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact IDEA AG, please visit www.idea-ag.de. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.